Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease
- PMID: 16505324
- DOI: 10.1212/01.WNL.0000198762.41312.E1
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease
Abstract
LY450139 dihydrate, a gamma-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Abeta(1-40) in plasma decreased by 38.2%; in CSF, Abeta(1-40) decreased by 4.42 +/- 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Abeta concentrations and a measurable decrease in CSF Abeta.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources